Vol.

No.

March 23, 2018Mar 23, 2018

DOWNLOAD THE PDF

Cover Story

Right to Try edges closer to becoming federal law

Libertarians rejoice, but can it solve compassionate use problems?

By Matthew Bin Han Ong

Few Washington insiders doubt that a bill that allows terminally ill patients to circumvent FDA as they pursue Hail Mary pass therapies will become the law of the land.

Conversation with The Cancer Letter

NYU's Caplan: Right to Try laws are meaningless, empty hot air, unethical, and utterly ineffective

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Goldwater's Coleman: Right to Try patients don't need permission from feds to save their own lives

By Matthew Bin Han Ong

How CMS intends to pay for next generation sequencing

By Paul Goldberg

Congressional omnibus gives NIH a surprisingly hefty $3 billion raise

By Paul Goldberg

In Brief

Robert Redfield to be named CDC director

UAMS to offer Arkansas' first-ever radiation oncology residency program

Andrew Aplin named first Kalbach-Newton professor at Thomas Jefferson

Jennifer Dorazio named Assistant director for administration at WVU

Cofactor Genomics announces collaboration with NCI

AbbVie and the International Myeloma Foundation partner to study role of a genetic mutation in multiple myeloma

Vanderbilt and Boehringer Ingelheim expand collaboration

Clinical Roundup

BioPharma publishes phase III COLUMBUS data of encorafenib and binimetinib

AVEO Oncology publishes long-term follow-up results from TIVO-1 Extension Study in TKI refractory RCC

Finasteride shown to prevent prostate cancer for up to 16 years

Machines see the future of patients diagnosed with brain tumors

Drugs & Targets

Novartis's Tasigna approved for children with rare form of leukemia

FDA approves Adcetris for adults with previously untreated stage III or IV classical Hodgkin lymphoma

University of Maryland certified for CAR T-cell therapy in lymphoma

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Right to Try edges closer to becoming federal law

NYU's Caplan: Right to Try laws are meaningless, empty hot air, unethical, and utterly ineffective

Goldwater's Coleman: Right to Try patients don't need permission from feds to save their own lives

How CMS intends to pay for next generation sequencing

Congressional omnibus gives NIH a surprisingly hefty $3 billion raise

In Brief

Robert Redfield to be named CDC director

UAMS to offer Arkansas' first-ever radiation oncology residency program

Andrew Aplin named first Kalbach-Newton professor at Thomas Jefferson

Jennifer Dorazio named Assistant director for administration at WVU

Cofactor Genomics announces collaboration with NCI

AbbVie and the International Myeloma Foundation partner to study role of a genetic mutation in multiple myeloma

Vanderbilt and Boehringer Ingelheim expand collaboration

Clinical Roundup

BioPharma publishes phase III COLUMBUS data of encorafenib and binimetinib

AVEO Oncology publishes long-term follow-up results from TIVO-1 Extension Study in TKI refractory RCC

Finasteride shown to prevent prostate cancer for up to 16 years

Machines see the future of patients diagnosed with brain tumors

Drugs & Targets

Novartis's Tasigna approved for children with rare form of leukemia

FDA approves Adcetris for adults with previously untreated stage III or IV classical Hodgkin lymphoma

University of Maryland certified for CAR T-cell therapy in lymphoma

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login